Join
Live feed
·
PRReleasevia Quantisnow
Tonix Pharmaceuticals Holding Corp. logo

Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology

ByQuantisnow·Wall Street's wire, on your screen.
TNXP· Tonix Pharmaceuticals Holding Corp.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TNXP (Tonix Pharmaceuticals Holding Corp.) and more on Quantisnow.

Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology | Quantisnow